🇺🇸 FDA
Pipeline program

Lonsurf 15 mg/6.14 mg film-coated tablets, FRUZAQLA 1 mg hard capsules, Lonsurf 20 mg/8.19 mg film-coated tablets, FRUZAQLA 5 mg hard capsules

ENGIC 06 FRUQUITAS

Phase 3 small_molecule active

Quick answer

Lonsurf 15 mg/6.14 mg film-coated tablets, FRUZAQLA 1 mg hard capsules, Lonsurf 20 mg/8.19 mg film-coated tablets, FRUZAQLA 5 mg hard capsules for metastatic oeso-gastric adenocarcinoma is a Phase 3 program (small_molecule) at CERO THERAPEUTICS HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
CERO THERAPEUTICS HOLDINGS, INC.
Indication
metastatic oeso-gastric adenocarcinoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials